호흡기질환 백신 시장 보고서(2026년)

Respiratory diseases encompass a variety of conditions that impact the lungs and airways, resulting in breathing difficulties and respiratory symptoms. A respiratory disease vaccine is a type of immunization aimed at protecting individuals from infections caused by viruses or bacteria that mainly target the respiratory system, including the lungs and airways. These vaccines function by triggering the immune system to generate antibodies that can identify and combat the specific pathogen responsible for the disease.

The main types of respiratory disease vaccines include viral vaccines, bacterial vaccines, and combination vaccines. A viral vaccine is a preparation containing weakened or inactivated viruses that trigger immune responses and are used to prevent respiratory diseases by preparing the immune system to recognize and combat specific viruses, thereby reducing infection spread and severity. They are applied in preventing infections such as COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, and others in infants, adolescents, and adults in clinics, hospitals, and other healthcare settings.

Tariffs have influenced the respiratory disease vaccine market by increasing the cost of raw materials, biopharmaceutical reagents, and manufacturing equipment, leading to higher production costs for vaccine manufacturers. This impact is particularly significant in segments like viral and bacterial vaccines and regions such as North America, Europe, and Asia-Pacific, where a large portion of vaccine components are imported. While tariffs pose challenges, they have also encouraged local production initiatives, boosting domestic manufacturing capabilities and supply chain resilience.

The respiratory disease vaccine market research report is one of a series of new reports from The Business Research Company that provides respiratory disease vaccine market statistics, including respiratory disease vaccine industry global market size, regional shares, competitors with a respiratory disease vaccine market share, detailed respiratory disease vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disease vaccine industry. This respiratory disease vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The respiratory disease vaccine market size has grown marginally in recent years. It will grow from $70.03 billion in 2025 to $71.36 billion in 2026 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to high prevalence of respiratory infections, limited availability of effective vaccines, government immunization initiatives, advancements in monoclonal antibody research, rising awareness about respiratory health.

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $81 billion in 2030 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to increasing demand for universal vaccines, technological advances in mRNA and viral vector vaccines, expansion of cold-chain infrastructure, growth in public-private partnerships for vaccine distribution, focus on pandemic preparedness and rapid response. Major trends in the forecast period include development of next-generation respiratory vaccines, increased focus on pediatric and geriatric immunization, expansion of immunization programs in emerging markets, rise of combination vaccines for multi-pathogen protection, adoption of rapid vaccine development and distribution platforms.

The increasing incidence of tuberculosis (TB) is expected to drive the growth of the respiratory disease vaccine market in the coming years. Tuberculosis is an infectious respiratory disease caused by Mycobacterium tuberculosis, mainly affecting the lungs and posing a major global health challenge. The rise in TB cases is influenced by factors such as weakened healthcare systems, delays in diagnosis, and wider transmission patterns, all contributing to a higher disease burden. Respiratory disease vaccines are essential in reducing TB-related risks by lowering infection rates, curbing transmission, and supporting global prevention efforts. For example, in March 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Thus, the growing incidence of tuberculosis is fueling the expansion of the respiratory disease vaccine market.

Major companies in the respiratory disease vaccine market are focusing on developing innovative products to improve their effectiveness and offer better solutions for preventing and managing respiratory disease infections. For example, in May 2023, Pfizer Inc., a US-based pharmaceutical company, obtained Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals aged 60 years and older. ABRYSVO is an unadjuvanted vaccine composed of two preF proteins designed to enhance immunity against RSV A and B strains and has been clinically demonstrated to be safe and effective.

In February 2024, AstraZeneca Plc, a UK-based biopharmaceutical company, acquired Icosavax, Inc. for an undisclosed amount. Through this acquisition, AstraZeneca aims to strengthen its vaccine development capabilities and broaden its pipeline of next-generation immunotherapies. Icosavax, Inc. is a US-based biotechnology company focused on developing virus-like particle (VLP) vaccines targeting infectious diseases.

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory disease vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the respiratory disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The respiratory diseases vaccine market consists of sales of the rotavirus vaccine, bordetella vaccine and varicella (chickenpox) vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Disease Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses respiratory disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The respiratory disease vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Viral Vaccine; Bacterial Vaccine; Combination Vaccine
• 2) By Infection: COVID-19; Influenza; Respiratory Syncytial Virus (RSV); Pneumonia; Other Infections
• 3) By Age: Infant; Adolescent; Adult
• 4) By End-User: Clinic; Hospital; Other End-Users
• Subsegments:
• 1) By Viral Vaccine: Influenza Vaccine; Respiratory Syncytial Virus (RSV) Vaccine; Coronavirus Vaccine
• 2) By Bacterial Vaccine: Pneumococcal Vaccine; Haemophilus Influenzae Type B (Hib) Vaccine; Pertussis Vaccine
• 3) By Combination Vaccine: DTaP With Hib And IPV; Pneumococcal Conjugate Vaccine With Influenza Vaccine
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; Merck & Co. Inc.; Sanofi SA; AstraZeneca PLC; GlaxoSmithKline PLC; Sinovac Biotech Co. Ltd.; Moderna Inc.; BioNTech SE; CSL Limited; Daiichi Sankyo Company Limited; Mitsubishi Tanabe Pharma Corporation; Novavax Inc.; Emergent BioSolutions Inc.; Seqirus; Bio Farma; Dynavax Technologies Corporation; Hualan Biological Bacterin Co. Ltd.; Serum Institute of India Pvt. Ltd.; Bavarian Nordic A/S; Valneva SE; Biological E. Limited; CanSino Biologics Inc.; Bharat Biotech International Limited; Medicago Inc; CureVac N.V.; Incepta Vaccine Ltd; Inovio Pharmaceuticals Inc.; Ology Bioservices; VBI Vaccines Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Respiratory Disease Vaccine Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Respiratory Disease Vaccine Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Respiratory Disease Vaccine Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Respiratory Disease Vaccine Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Development of Next-Generation Respiratory Vaccines
  • 4.2.2 Increased Focus on Pediatric and Geriatric Immunization
  • 4.2.3 Expansion of Immunization Programs in Emerging Markets
  • 4.2.4 Rise of Combination Vaccines for Multi-Pathogen Protection
  • 4.2.5 Adoption of Rapid Vaccine Development and Distribution Platforms

5. Respiratory Disease Vaccine Market Analysis Of End Use Industries

• 5.1 Clinics
• 5.2 Hospitals
• 5.3 Government Immunization Centers
• 5.4 Pharmaceutical Companies
• 5.5 Research Laboratories

6. Respiratory Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Respiratory Disease Vaccine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Respiratory Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Respiratory Disease Vaccine Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Respiratory Disease Vaccine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Respiratory Disease Vaccine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Respiratory Disease Vaccine Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Respiratory Disease Vaccine Market Segmentation

• 9.1. Global Respiratory Disease Vaccine Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Viral Vaccine, Bacterial Vaccine, Combination Vaccine
• 9.2. Global Respiratory Disease Vaccine Market, Segmentation By Infection, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections
• 9.3. Global Respiratory Disease Vaccine Market, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Infant, Adolescent, Adult
• 9.4. Global Respiratory Disease Vaccine Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Clinic, Hospital, Other End-Users
• 9.5. Global Respiratory Disease Vaccine Market, Sub-Segmentation Of Viral Vaccine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine
• 9.6. Global Respiratory Disease Vaccine Market, Sub-Segmentation Of Bacterial Vaccine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine
• 9.7. Global Respiratory Disease Vaccine Market, Sub-Segmentation Of Combination Vaccine, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine

10. Respiratory Disease Vaccine Market Regional And Country Analysis

• 10.1. Global Respiratory Disease Vaccine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Respiratory Disease Vaccine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Respiratory Disease Vaccine Market

• 11.1. Asia-Pacific Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Respiratory Disease Vaccine Market

• 12.1. China Respiratory Disease Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Respiratory Disease Vaccine Market

• 13.1. India Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Respiratory Disease Vaccine Market

• 14.1. Japan Respiratory Disease Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Respiratory Disease Vaccine Market

• 15.1. Australia Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Respiratory Disease Vaccine Market

• 16.1. Indonesia Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Respiratory Disease Vaccine Market

• 17.1. South Korea Respiratory Disease Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Respiratory Disease Vaccine Market

• 18.1. Taiwan Respiratory Disease Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Respiratory Disease Vaccine Market

• 19.1. South East Asia Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Respiratory Disease Vaccine Market

• 20.1. Western Europe Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Respiratory Disease Vaccine Market

• 21.1. UK Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Respiratory Disease Vaccine Market

• 22.1. Germany Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Respiratory Disease Vaccine Market

• 23.1. France Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Respiratory Disease Vaccine Market

• 24.1. Italy Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Respiratory Disease Vaccine Market

• 25.1. Spain Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Respiratory Disease Vaccine Market

• 26.1. Eastern Europe Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Respiratory Disease Vaccine Market

• 27.1. Russia Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Respiratory Disease Vaccine Market

• 28.1. North America Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Respiratory Disease Vaccine Market

• 29.1. USA Respiratory Disease Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Respiratory Disease Vaccine Market

• 30.1. Canada Respiratory Disease Vaccine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Respiratory Disease Vaccine Market

• 31.1. South America Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Respiratory Disease Vaccine Market

• 32.1. Brazil Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Respiratory Disease Vaccine Market

• 33.1. Middle East Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Respiratory Disease Vaccine Market

• 34.1. Africa Respiratory Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Respiratory Disease Vaccine Market, Segmentation By Type, Segmentation By Infection, Segmentation By Age, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Respiratory Disease Vaccine Market Regulatory and Investment Landscape

36. Respiratory Disease Vaccine Market Competitive Landscape And Company Profiles

• 36.1. Respiratory Disease Vaccine Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Respiratory Disease Vaccine Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Respiratory Disease Vaccine Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

37. Respiratory Disease Vaccine Market Other Major And Innovative Companies

• GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S

38. Global Respiratory Disease Vaccine Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Respiratory Disease Vaccine Market

40. Respiratory Disease Vaccine Market High Potential Countries, Segments and Strategies

• 40.1 Respiratory Disease Vaccine Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Respiratory Disease Vaccine Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Respiratory Disease Vaccine Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer